Jan 16, 2020 / 05:00PM GMT
Gabriel Cruz;JPMorgan;Analyst -
Good morning. My name is Gabriel Cruz, and I'm a member of the health care investment banking team here at JPMorgan. Thank you all for joining us today. Today, I have the pleasure of presenting Scott Koenig, CEO of MacroGenics.
Scott Koenig - MacroGenics, Inc. - CEO, President & Director
Thank you very much. So thank you very much for the opportunity to present at JPMorgan. I will be presenting forward-looking statements during the course of this presentation. So please refer to our SEC filings to understand the risks associated with an investment in MacroGenics.
MacroGenics is a leader in the development of antibody therapeutics for the treatment of cancer. We have developed our company through our core platform technology developed in-house. First one is Fc-engineering, where we've incorporated this technology in 2 of our molecules and have demonstrated coordinate activation of the innate and specific immune responses to produce clinical benefit.
Our second core technology is
MacroGenics Inc at JPMorgan Healthcare Conference Transcript
Jan 16, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers